39.65
price down icon2.24%   -0.91
pre-market  プレマーケット:  39.01   -0.64   -1.61%
loading
前日終値:
$40.56
開ける:
$40.53
24時間の取引高:
513.31K
Relative Volume:
0.88
時価総額:
$2.30B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
3.4903
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-1.73%
1か月 パフォーマンス:
+18.64%
6か月 パフォーマンス:
+15.06%
1年 パフォーマンス:
-17.72%
1日の値動き範囲:
Value
$39.22
$40.98
1週間の範囲:
Value
$38.48
$41.19
52週間の値動き範囲:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1161)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
488
Name
Twitter
@AgiosPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

AGIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
39.65 2.35B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
12:24 PM

Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional

12:24 PM
pulisher
Jul 24, 2025

Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Agios Pharmaceuticals Inc. stock priceTriple-digit returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Agios Pharmaceuticals Inc. stockFree Consultation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus

Jul 22, 2025
pulisher
Jul 21, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Jul 21, 2025
pulisher
Jul 18, 2025

What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jul 18, 2025
pulisher
Jul 15, 2025

why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Public market insider buying at Extendicare (EXE) - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Trend Tracker for (AGIO) - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Agios pharma chief medical officer Gheuens sells $452,601 in stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 09, 2025

Agios Pharmaceuticals Inc. (AGIO) Shares Soar 7.69% on FDA Designation - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Agios Pharma Appoints Dr. Jay Backstrom as Director - The Globe and Mail

Jul 09, 2025
pulisher
Jul 09, 2025

Agios Pharmaceuticals appoints Jay Backstrom to board of directors By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors. - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom To Board - citybiz

Jul 08, 2025
pulisher
Jul 08, 2025

Agios appoints Dr. Jay Backstrom to board of directors - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom to Board of Directors - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals Appoints Dr. Jay Backstrom to Board of Directors - Quiver Quantitative

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom to Board of Directors | AGIO St - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals appoints Jay Backstrom to board of directors - Investing.com India

Jul 08, 2025
pulisher
Jul 07, 2025

H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN

Jul 07, 2025
pulisher
Jun 30, 2025

Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Agios pharma chief legal officer Burns sells $93k in stock - Investing.com

Jun 26, 2025
pulisher
Jun 18, 2025

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews

Jun 17, 2025

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
大文字化:     |  ボリューム (24 時間):